Tandem Diabetes Care, Inc. , a medical device company, designs, develops, and commercializes various products for people with insulin-dependent diabetes in the United States. The company’s flagship product is the t:slim X2 insulin delivery system that comprises t:slim X2 pump, its disposable insulin cartridge, and an infusion set. It also provides t:flex insulin delivery system that includes t:flex pump, its 480-unit disposable insulin cartridge, and an infusion set; and t:slim G4 insulin delivery system, a touch-screen pump with an integrated CGM system. In addition, the company offers Tandem Device Updater, a PC and Mac-compatible Web-based system that allows users to update their pump’s software; t:connect diabetes management application, a cloud-based data management application, which provides a visual way to display therapy management data from the pump and supported blood glucose meters for users, their caregivers, and their healthcare providers; t:90 and t:30 infusion sets for use with its insulin pump products; and various pump accessories. Its products in development include t:slim X2 with G5 integration; automated insulin delivery systems; t:slim X2 with PLGS; t:slim X2 with TypeZero; and t:sport insulin delivery system. The company was formerly known as Phluid Inc. and changed its name to Tandem Diabetes Care, Inc. in January 2008. Tandem Diabetes Care, Inc. was founded in 2006 and is headquartered in San Diego, California.

  • Hedge Funds Are Buying Tandem Diabetes Care Inc (TNDM) Again
    on September 15, 2020 at 1:06 pm

    The latest 13F reporting period has come and gone, and Insider Monkey have plowed through 823 13F filings that hedge funds and well-known value investors are required to file by the SEC. The 13F filings show the funds' and investors' portfolio positions as of June 30th, when the S&P 500 Index was trading around the

  • Tandem Diabetes Care Announces Upcoming Webcast Conference Presentations
    on September 2, 2020 at 8:05 pm

    Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, today announced that John Sheridan, president and chief executive officer, will present a company update at the following virtual investor conferences:

  • Tandem Diabetes' Advanced Insulin Pump Study Results Favorable
    on August 28, 2020 at 12:26 pm

    Per the DCLP5 study, Tandem Diabetes' (TNDM) insulin pump with Control-IQ technology suitable for use in children aged six to 13 years, which has been published in the NEJM.

  • Does Tandem Diabetes Care (NASDAQ:TNDM) Have A Healthy Balance Sheet?
    on August 27, 2020 at 7:55 pm

    Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...

  • Tandem Diabetes Care Announces NEJM Publication of Pediatric Study Demonstrating Increased Time-In-Range using the t:slim X2 Insulin Pump with Control-IQ Technology
    on August 27, 2020 at 12:30 pm

    Tandem announces New England Journal of Medicine publication of pediatric study showing increased time in range with Control-IQ technology.

  • Benzinga's Top Upgrades, Downgrades For August 20, 2020
    on August 20, 2020 at 1:51 pm

    Upgrades * For Cinemark Holdings Inc (NYSE: CNK), Benchmark upgraded the previous rating of Hold to the current rating Buy. For the second quarter, Cinemark Hldgs had an EPS of $1.27, compared to year-ago quarter EPS of $0.86. The stock has a 52-week-high of $39.81 and a 52-week-low of $5.71. At the end of the last trading period, Cinemark Hldgs closed at $11.14. * For OGE Energy Corp (NYSE: OGE), Guggenheim upgraded the previous rating of Neutral to the current rating Buy. OGE Energy earned $0.51 in the second quarter, compared to $0.50 in the year-ago quarter. The stock has a 52-week-high of $46.43 and a 52-week-low of $23.00. At the end of the last trading period, OGE Energy closed at $32.08. * According to Northland Capital Markets, the prior rating for Power Integrations Inc (NASDAQ: POWI) was changed from Underperform to Market Perform. For the second quarter, Power Integrations had an EPS of $0.66, compared to year-ago quarter EPS of $0.56. At the moment, the stock has a 52-week-high of $127.39 and a 52-week-low of $56.88. Power Integrations closed at $57.30 at the end of the last trading period. * According to DBS Bank, the prior rating for Sea Ltd (NYSE: SE) was changed from Sell to Buy. For the second quarter, Sea had an EPS of $0.68, compared to year-ago quarter EPS of $0.68. At the moment, the stock has a 52-week-high of $154.25 and a 52-week-low of $26.41. Sea closed at $150.58 at the end of the last trading period. * For Shake Shack Inc (NYSE: SHAK), Wedbush upgraded the previous rating of Neutral to the current rating Outperform. For the second quarter, Shake Shack had an EPS of $0.45, compared to year-ago quarter EPS of $0.27. The current stock performance of Shake Shack shows a 52-week-high of $105.84 and a 52-week-low of $30.01. Moreover, at the end of the last trading period, the closing price was at $53.87. * According to Barclays, the prior rating for Dana Inc (NYSE: DAN) was changed from Equal-Weight to Overweight. In the second quarter, Dana showed an EPS of $0.69, compared to $0.87 from the year-ago quarter. The stock has a 52-week-high of $19.21 and a 52-week-low of $4.22. At the end of the last trading period, Dana closed at $13.17. * For Elanco Animal Health Inc (NYSE: ELAN), Morgan Stanley upgraded the previous rating of Equal-Weight to the current rating Overweight. For the second quarter, Elanco Animal Health had an EPS of $0.09, compared to year-ago quarter EPS of $0.28. At the moment, the stock has a 52-week-high of $32.66 and a 52-week-low of $15.17. Elanco Animal Health closed at $25.80 at the end of the last trading period. Downgrades * For Vipshop Holdings Ltd (NYSE: VIPS), JP Morgan downgraded the previous rating of Overweight to the current rating Neutral. For the second quarter, Vipshop Holdings had an EPS of $0.27, compared to year-ago quarter EPS of $0.23. The stock has a 52-week-high of $24.46 and a 52-week-low of $7.69. At the end of the last trading period, Vipshop Holdings closed at $19.26. * According to Raymond James, the prior rating for Ventas Inc (NYSE: VTR) was changed from Strong Buy to Outperform. Ventas earned $0.77 in the second quarter, compared to $0.97 in the year-ago quarter. At the moment, the stock has a 52-week-high of $75.40 and a 52-week-low of $13.35. Ventas closed at $40.38 at the end of the last trading period. * According to Benchmark, the prior rating for Regeneron Pharmaceuticals Inc (NASDAQ: REGN) was changed from Buy to Hold. For the second quarter, Regeneron Pharmaceuticals had an EPS of $7.16, compared to year-ago quarter EPS of $6.04. The current stock performance of Regeneron Pharmaceuticals shows a 52-week-high of $664.64 and a 52-week-low of $271.37. Moreover, at the end of the last trading period, the closing price was at $629.63. * For Biomarin Pharmaceutical Inc (NASDAQ: BMRN), RBC Capital downgraded the previous rating of Outperform to the current rating Sector Perform. Biomarin Pharmaceutical earned $0.16 in the second quarter, compared to $0.29 in the year-ago quarter. The current stock performance of Biomarin Pharmaceutical shows a 52-week-high of $131.94 and a 52-week-low of $62.88. Moreover, at the end of the last trading period, the closing price was at $76.72. * Wells Fargo downgraded the previous rating for Crown Castle International Corp (NYSE: CCI) from Overweight to Equal-Weight. In the second quarter, Crown Castle Intl showed an EPS of $1.45, compared to $1.41 from the year-ago quarter. The stock has a 52-week-high of $180.00 and a 52-week-low of $114.18. At the end of the last trading period, Crown Castle Intl closed at $162.69. * For Momenta Pharmaceuticals Inc (NASDAQ: MNTA), Stifel downgraded the previous rating of Buy to the current rating Hold. Momenta Pharmaceuticals earned $0.48 in the second quarter, compared to $1.16 in the year-ago quarter. The current stock performance of Momenta Pharmaceuticals shows a 52-week-high of $52.21 and a 52-week-low of $11.91. Moreover, at the end of the last trading period, the closing price was at $52.12. * For Principia Biopharma Inc (NASDAQ: PRNB), Stifel downgraded the previous rating of Buy to the current rating Hold. Principia Biopharma earned $0.31 in the second quarter, compared to $0.28 in the year-ago quarter. The stock has a 52-week-high of $100.04 and a 52-week-low of $25.35. At the end of the last trading period, Principia Biopharma closed at $99.70. * For Teligent Inc (NASDAQ: TLGT), Craig-Hallum downgraded the previous rating of Buy to the current rating Hold. Teligent earned $1.54 in the second quarter, compared to $0.04 in the year-ago quarter. At the moment, the stock has a 52-week-high of $5.94 and a 52-week-low of $0.19. Teligent closed at $2.01 at the end of the last trading period. * Credit Suisse downgraded the previous rating for Sarepta Therapeutics Inc (NASDAQ: SRPT) from Outperform to Neutral. In the second quarter, Sarepta Therapeutics showed an EPS of $1.51, compared to $0.83 from the year-ago quarter. The stock has a 52-week-high of $175.00 and a 52-week-low of $72.05. At the end of the last trading period, Sarepta Therapeutics closed at $148.66. Initiations * Deutsche Bank initiated coverage on Check Point Software Technologies Ltd (NASDAQ: CHKP) with a Hold rating. The price target for Check Point Software is set to $128.00. Check Point Software earned $1.58 in the second quarter, compared to $1.38 in the year-ago quarter. The current stock performance of Check Point Software shows a 52-week-high of $130.65 and a 52-week-low of $80.06. Moreover, at the end of the last trading period, the closing price was at $128.08. * With a current rating of Outperform, Evercore ISI Group initiated coverage on 8x8 Inc (NYSE: EGHT). The price target seems to have been set at $23.00 for 8x8. 8x8 earned $0.07 in the first quarter, compared to $0.14 in the year-ago quarter. The stock has a 52-week-high of $25.25 and a 52-week-low of $10.70. At the end of the last trading period, 8x8 closed at $16.28. * Morgan Stanley initiated coverage on ACADIA Pharmaceuticals Inc (NASDAQ: ACAD) with an Overweight rating. The price target for ACADIA Pharmaceuticals is set to $55.00. In the second quarter, ACADIA Pharmaceuticals showed an EPS of $0.27, compared to $0.38 from the year-ago quarter. The current stock performance of ACADIA Pharmaceuticals shows a 52-week-high of $58.72 and a 52-week-low of $23.77. Moreover, at the end of the last trading period, the closing price was at $38.91. * Deutsche Bank initiated coverage on Fortinet Inc (NASDAQ: FTNT) with a Hold rating. The price target for Fortinet is set to $131.00. Fortinet earned $0.82 in the second quarter, compared to $0.58 in the year-ago quarter. The current stock performance of Fortinet shows a 52-week-high of $151.95 and a 52-week-low of $70.20. Moreover, at the end of the last trading period, the closing price was at $129.51. * Needham initiated coverage on Vir Biotechnology Inc (NASDAQ: VIR) with a Buy rating. The price target for Vir Biotechnology is set to $62.00. Vir Biotechnology earned $0.27 in the second quarter. At the moment, the stock has a 52-week-high of $75.00 and a 52-week-low of $11.65. Vir Biotechnology closed at $50.43 at the end of the last trading period. * Morgan Stanley initiated coverage on Evofem Biosciences Inc (NASDAQ: EVFM) with a Equal-Weight rating. In the second quarter, Evofem Biosciences showed an EPS of $0.39, compared to $0.95 from the year-ago quarter. The stock has a 52-week-high of $7.50 and a 52-week-low of $2.73. At the end of the last trading period, Evofem Biosciences closed at $3.36. * With a current rating of In-Line, Evercore ISI Group initiated coverage on Five9 Inc (NASDAQ: FIVN). The price target seems to have been set at $122.00 for Five9. For the second quarter, Five9 had an EPS of $0.21, compared to year-ago quarter EPS of $0.20. The stock has a 52-week-high of $131.98 and a 52-week-low of $50.73. At the end of the last trading period, Five9 closed at $124.59. * Oppenheimer initiated coverage on Fulgent Genetics Inc (NASDAQ: FLGT) with an Outperform rating. The price target for Fulgent Genetics is set to $75.00. Fulgent Genetics earned $0.17 in the second quarter, compared to $0.06 in the year-ago quarter. At the moment, the stock has a 52-week-high of $47.85 and a 52-week-low of $6.70. Fulgent Genetics closed at $44.01 at the end of the last trading period. * Goldman Sachs initiated coverage on Flexion Therapeutics Inc (NASDAQ: FLXN) with a Neutral rating. The price target for Flexion Therapeutics is set to $15.00. Flexion Therapeutics earned $0.76 in the second quarter, compared to $0.96 in the year-ago quarter. The current stock performance of Flexion Therapeutics shows a 52-week-high of $22.98 and a 52-week-low of $5.01. Moreover, at the end of the last trading period, the closing price was at $12.65. * With a current rating of Overweight, Wells Fargo initiated coverage on Tandem Diabetes Care Inc (NASDAQ: TNDM). The price target seems to have been set at $120.00 for Tandem Diabetes Care. For the second quarter, Tandem Diabetes Care had an EPS of $0.45, compared to year-ago quarter EPS of $0.03. The stock has a 52-week-high of $110.80 and a 52-week-low of $43.69. At the end of the last trading period, Tandem Diabetes Care closed at $107.33. * Berenberg initiated coverage on Eaton Corp PLC (NYSE: ETN) with a Hold rating. The price target for Eaton Corp is set to $110.00. Eaton Corp earned $0.70 in the second quarter, compared to $1.53 in the year-ago quarter. At the moment, the stock has a 52-week-high of $105.78 and a 52-week-low of $56.41. Eaton Corp closed at $100.48 at the end of the last trading period. * With a current rating of Buy, Berenberg initiated coverage on Emerson Electric Co (NYSE: EMR). The price target seems to have been set at $83.00 for Emerson Electric. For the third quarter, Emerson Electric had an EPS of $0.80, compared to year-ago quarter EPS of $0.94. The current stock performance of Emerson Electric shows a 52-week-high of $78.38 and a 52-week-low of $37.75. Moreover, at the end of the last trading period, the closing price was at $68.32. * With a current rating of Buy, Berenberg initiated coverage on Rockwell Automation Inc (NYSE: ROK). The price target seems to have been set at $270.00 for Rockwell Automation. In the third quarter, Rockwell Automation showed an EPS of $1.27, compared to $2.40 from the year-ago quarter. At the moment, the stock has a 52-week-high of $238.49 and a 52-week-low of $115.38. Rockwell Automation closed at $228.68 at the end of the last trading period.See more from Benzinga * Morning Market Stats in 5 Minutes * A Look Into FMC's Debt * What Does Cal-Maine Foods's Debt Look Like?(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

  • 3 Top Diabetes Stocks to Buy in August
    on August 13, 2020 at 9:11 am

    DexCom, Tandem Diabetes, and Novo Nordisk have plenty of momentum and growth ahead, making them excellent buys this month.

  • Tandem Diabetes Care Inc (TNDM) Q2 2020 Earnings Call Transcript
    on July 31, 2020 at 5:30 pm

    TNDM earnings call for the period ending June 30, 2020.

  • Tandem Diabetes (TNDM) Q2 Earnings & Revenues Top Estimates
    on July 31, 2020 at 1:59 pm

    Tandem Diabetes' (TNDM) strong domestic pump sales and pump shipments boosted the top line.

  • How Top Fund Managers Spot Tomorrow's Stock Winners Early
    on July 31, 2020 at 12:00 pm

    Federated Hermes Kaufmann Small Cap is one of the best mutual funds as it gets in early on innovative small-company stocks with big potential.

[custom-facebook-feed id=TandemDiabetes ownaccesstoken=true pagetype=page seemoretext=’Expand’ ajax=true]

Thanks to all these real users who shared their experiences on Control-IQ technology! If you'd like to share your own video on how Control-IQ technology changed your life, please visit: http://www.tandemdiabetes.com/hcitcml
RX ONLY. For boxed warning & indications: http://tandemdiabetes.com/safetyinfo

Mark Andrews (@Mandrews_81) had an amazing game and scored 18 fantasy points on Sunday. That means we’re donating $2,700 to @JDRF! Don’t forget that you can join in and pledge your own donation and learn about the campaign at https://www.tandemdiabetes.com/landing-pages/mark-andrews.

Upside of #SocialDistancing? Finding new places for your #tsliminthewild pictures! These t:slim X2 #diabuddies got creative and went ziplining, masks and all! Where have you #SocialDistanced with your #tslimx2? RX ONLY. For boxed warning & indications: http://tandemdiabetes.com/safetyinfo

Introducing our fantasy football charity challenge! For every fantasy point Mark Andrews scores during the 2020-2021 season, we’ll donate $150 to @JDRF (up to $25,000 total). Remember: every point gets us one yard closer to a cure. http://www.tandemdiabetes.com/landing-pages/mark-andrews

If you or someone you know is affected by the fires in CA and OR and are having difficulty accessing supplies for a Tandem pump, our Support team is available 24/7 at 1-877-801-6901 and can help coordinate with local resources. Evacuation packing list:
https://www.tandemdiabetes.com/blog/post/general/2017/09/07/emergency-evacuation%E2%80%93insulin-pump-supplies-packing-list

Load More...

FULL NAME*

What's Your Role?*

WORK EMAIL*

COMPANY NAME*

Company Description*

HOW'D YOU HEAR ABOUT US?

DETAILS ABOUT YOUR GOALS

Tandem Diabetes Care, Inc.

11045 Roselle Street
San Diego, CA 92121

+1 (858) 366-6900

www.tandemdiabetes.com

September 2020
S M T W T F S
 12345
6789101112
13141516171819
20212223242526
27282930  

©2020 ALIGNMT LLC | Alignment Strategy | Mergers & Acquisitions | Investor Relations

CONTACT US

We're not around right now. But you can send us an email and we'll get back to you, asap.

Sending

Log in with your credentials

or    

Forgot your details?

Create Account